The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice

Journal of Hepatology

Volumn 56, Issue 2, 2012, Pages 503-504

  Weiss, Jeffrey J ^a   Alcorn, Marlene C ^a   Rabkin, Judith G ^b   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; TELAPREVIR;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; EPILEPSY; FOOD INTAKE; HEART FAILURE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE; OLIGOPEPTIDES; PROLINE;

EID: 84855935309     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.05.014     Document Type: Letter

References (10)

1. J.J. Weiss, N. Brau, A. Stivala, T. Swan, and D. Fishbein Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Aliment Pharmacol Ther 30 2009 14 27
2. S.R. Smith, A.S. Wahed, S.S. Kelley, H.S. Conjeevaram, P.R. Robuck, and M.W. Fried Assessing the validity of self-reported medication adherence in hepatitis C treatment Ann Pharmacother 41 2007 1116 1123 (Pubitemid 47122547)
3. S.D. Saini, P. Schoenfeld, K. Kaulback, and M.C. Dubinsky Effect of medication dosing frequency on adherence in chronic diseases Am J Manage Care 15 2009 E22 E33
4. R. Straka, J. Fish, S. Benson, and J. Suh Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease J Clin Pharmacol 36 1996 587 594 (Pubitemid 26260538)
5. D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, and C. Squier Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 2000 21 30 (Pubitemid 30432540)
6. J. Cramer, L. Vachon, C. Desforges, and N.M. Sussman Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial Epilepsia 36 1995 1111 1117
7. A.H. Paes, A. Bakker, and C.J. Soe-Agnie Impact of dosage frequency on patient compliance Diabetes Care 20 1997 1512 1517 (Pubitemid 27415025)
8. P. Bohachick, L.E. Burke, S. Sereika, S. Murali, and J. Dunbar-Jacob Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure Prog Cardiovasc Nurs 17 2002 160 166
9. S.C. Gordon, E.J. Lawitz, B.R. Bacon, M.S. Sulkowski, E.M. Yoshida, and M. Davis 428 Adherence to assigned dosing regimen and sustained virologic response among hepatitis c genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin J Hepatol 54 2011 S173 S174
10. P. Marcellin, X. Forns, T. Goeser, P. Ferenci, F. Nevens, and G. Carosi Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 140 2011 459 468